BioVex Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioVex Group, Inc.
Minute Insight: New Butterfly Network CEO Has Tough Job Ahead
The handheld ultrasound company made a loss last quarter, but secured FDA authorization for a new ultrasound software and named new leadership.
Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
Exec Chat: Butterfly Network Brings Maternal Ultrasound To Underserved Regions
Medtech Insight talked to Sachita Shah, Butterfly Network's director of global health, and John Martin, the company's chief medical officer, to learn more about how point-of-care ultrasound can benefit rural, underserved communities in Sub-Saharan Africa by helping to reduce maternal mortality and childbirth-related complications.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.